OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

trialsTrialNegative

RTOG 0617

RTOG 0617 is the trial that stopped dose escalation in lung cancer: patients given 74 Gy lived shorter than those given the standard 60 Gy, and cetuximab added nothing.